The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology,
The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology, acquiring a sophisticated power injector system from Swiss-based manufacturer Bruker. Called Tomoject, this pump injector provides the constant and reliable flow of contrast media necessary for ultrafast imaging, including contrast-enhanced angiography, tumor diagnostics, organ perfusion, and incremental body imaging. Tomoject is currently marketed in Europe and other international venues. The manufacturing site will remain Zurich.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.